Physician profile

Peter Maduka

Philadelphia, PA

$2,679.67

in general payments reported to CMS, 2019-2025

3 companies · $324 in 2025

The $324 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,510.83
Travel and Lodging$1,168.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bausch & Lomb Americas INC. $2,097.31 2024-2025 Envista Mx60 Iol, Crystalens Accommodating Iol (At-52ao), Stellaris Elite
Alcon Vision LLC $559.94 2023-2024 Clareon, Hydrus Microstent
Abbvie INC. $22.42 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter Maduka

$2,679.67

in general payments reported 2019-2025

Years
2023-2025
Top company
Bausch & Lomb Americas INC.
Context
The $324 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11553239/peter-maduka

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.